瑞舒伐他汀钙片治疗原发性高胆固醇血症的临床研究  

Clinical trial of rosuvastatin calcium tablets in the treatment of patients with primary hypercholesterolemia

作　　者：曲玉峰[1] 宗桂芝 

机构地区：[1]北京京煤集团总医院内分泌科,北京102300

出　　处：《中国临床药理学杂志》2017年第15期1412-1414,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察瑞舒伐他汀钙片对原发性高胆固醇血症患者的临床疗效及其对患者血清超敏C反应蛋白(hs-CRP)、可溶性血管细胞黏附因子^(-1)(s VCAM^(-1))的影响。方法将86例原发性高胆固醇血症患者分为试验组与对照组,每组43例。对照组患者给予阿托伐他汀钙片10 mg·d^(-1),口服;试验组患者给予瑞舒伐他汀钙片10 mg·d^(-1),口服。2组患者均治疗8周。比较2组患者的临床疗效、血脂水平及血清hs-CRP、s VCAM^(-1)水平。结果治疗后,试验组总有效率为95.35%(41/43例),对照组为79.07%(34/43例,P<0.05)。治疗后,试验组血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)分别为(4.38±0.89),(1.54±0.79),(2.23±0.82)mmol·L^(-1),对照组分别为(4.79±0.87),(1.90±0.83),(2.61±0.89)mmol·L^(-1),差异有统计学意义(P<0.05)。治疗后,试验组和对照组hs-CRP分别为(4.83±1.13),(5.12±1.78)mg·L^(-1),s VCAM^(-1)分别为(0.37±0.15),(0.39±0.13)mg·L^(-1),差异有统计学意义(P<0.05)。2组患者主要的药物不良反应为便秘、腹痛、恶心,试验组和对照组药物不良反应发生率分别为11.63%(5/43例),13.95%(6/43例),差异无统计学意义(P>0.05)。结论瑞舒伐他汀钙片治疗原发性高胆固醇血症有较好的临床疗效和安全性。Objective To observe the clinical efficacy of rosuvastatin calcium tablets in the treatment of patients with primary hypercholesterolemia and its effects on the serum high sensitivity reactive protein（ hs-CRP）and soluble vascular cell adhesion factor^-1（ s VCAM^-1）. Methods Eighty-six patients with primary hypercholesterolemia were divided into treatment group and control group,43 cases in each group. Control group was treated with atorvastatin calcium tablets 10 mg · d^-1, orally.Treatment group was treated with rosuvastatin calcium tablets 10mg·d^-1,orally. All patients were treated for 8 weeks. The clinical efficacy,blood lipids and levels of serum hs-CRP,s VCAM^-1 were compared between two groups. Results After treatment, the total effective rates in treatment group and control group were 95. 35%（ 41/43cases）, 79. 07%（ 34/43 cases）, with significant difference（ P〈0. 05）. The total cholesterol（ TC）, triglyceride（ TG） and low-density lipoprotein（ LDL-C） in treatment group were（ 4. 38 ± 0. 89）,（ 1. 54 ± 0. 79）,（ 2. 23 ± 0. 82） mmol · L^-1,hadsignificant difference with those in control group,which were（ 4. 79 ± 0. 87）,（ 1. 90 ± 0. 83）,（ 2. 61 ± 0. 89）mmol·L^-1（ P〈0. 05）. The levels of hs-CRP in treatment group and control group were（ 4. 83 ± 1. 13）,（ 5. 12 ± 1. 78） mg·L^-1. The levels of s VCAM^-1 in treatment group and control group were（ 0. 37 ± 0. 15）,（ 0. 39 ± 0. 13） mg · L^-1,with significant difference（ P〈0. 05）. The adverse drug reactions in two groups were constipation,abdominal pain,nausea. The incidence of adverse drug reactions in treatment group and control group were 11. 63%（ 5/43 cases）,13. 95%（ 6/43 cases）,without significant difference（ P〈0. 05）. Conclusion Rosuvastatin calcium tablet has good clinical efficacy in the treatment of primary hypercholes-terolemia,with high safety.

关 键 词：原发性高胆固醇血症 阿托伐他汀钙片 瑞舒伐他汀钙片 超敏C反应蛋白 可溶性血管细胞黏附因子-1 

分 类 号：R972[医药卫生—药品]